• Duff GW (2006). Expert Scientific Group on Phase One Clinical Trials Final Report. Stationery Office: Norwich, UK.
  • Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M et al. (2010). Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161: 512526.
  • EMA, European Medicines Agency (2007). Guideline on strategies to identify and mitigate risks for first-in human clinical trials with investigational medicinal products.
  • Gogishvili T, Langenhorst D, Luhder F, Elias F, Elflein K, Dennehy KM et al. (2009). Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. Plos ONE 4: e4643.
  • Hanke T (2006). Lessons from TGN1412. Lancet 368: 15691570. author reply 1570.
  • Hunig T (2007). Manipulation of regulatory T-Cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 95: 111148.
  • Kenter MJ, Cohen AF (2006). Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368: 13871391.
  • Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VC et al. (2002). Development and homeostasis of T cell memory in rhesus macaque. J Immunol 168: 2943.
  • Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 10181028.